secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-08-06T12:30:36+00:00
Accession:  0001104659-26-091691
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q2 net loss $0.07/sh; closes $130M notes; OCU410 Phase 3 cleared by FDA
------------------------------------------------------------------------------

- Net loss $24.9M ($0.07/sh) vs $14.7M ($0.05/sh) in Q2 2025; operating expenses $17.9M.
- Cash $100.4M as of June 30, 2026; closed $130M 6.75% convertible notes due 2034, net $112.5M.
- FDA clearance to initiate OCU410 Phase 3 for geographic atrophy; RMAT designation granted.
- Signed binding term sheet with Roots Pharmaceutical for OCU400 license in MENA: up to $255M milestones + 22% royalty.
- OCU400 RP Phase 3 enrollment complete (N=140); topline Q1 2027. OCU410ST Stargardt enrollment complete (63 subjects); topline Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/0001104659-26-091691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer